TY  - JOUR
AU  - Herrero-Aguayo, Vicente
AU  - Saez-Martinez, Prudencio
AU  - Jimenez-Vacas, Juan M
AU  - Moreno-Montilla, M Trinidad
AU  - Montero-Hidalgo, Antonio J
AU  - Perez-Gomez, Jesus M
AU  - Lopez-Canovas, Juan L
AU  - Porcel-Pastrana, Francisco
AU  - Carrasco-Valiente, Julia
AU  - Anglada, Francisco J
AU  - Gomez-Gomez, Enrique
AU  - Yubero-Serrano, Elena M
AU  - Ibañez-Costa, Alejandro
AU  - Herrera-Martinez, Aura D
AU  - Sarmento-Cabral, Andre
AU  - Gahete, Manuel D
AU  - Luque, Raul M
PY  - 2022
DO  - 10.1016/j.omtn.2022.02.010
SN  - 2162-2531
UR  - http://hdl.handle.net/10668/22459
T2  - Molecular therapy. Nucleic acids
AB  - Prostate-specific antigen (PSA) is the gold-standard marker to screen prostate cancer (PCa) nowadays. Unfortunately, its lack of specificity and sensitivity makes the identification of novel tools to diagnose PCa an urgent medical need. In this...
LA  - en
PB  - Cell Press
KW  - FASN
KW  - PSA
KW  - miR-107
KW  - miRNome
KW  - Non-invasive biomarker
KW  - Obesity
KW  - Prostate cancer
KW  - MicroRNAs
KW  - Prostate-specific antigen
KW  - ROC curve
KW  - Lipid metabolism
KW  - Body mass index
KW  - Prostatic neoplasms
KW  - Cell proliferation
TI  - Dysregulation of the miRNome unveils a crosstalk between obesity and prostate cancer: miR-107 asa personalized diagnostic and therapeutic tool.
TY  - research article
VL  - 27
ER  -